In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon Q2 guidance

This article was originally published in The Rose Sheet

Executive Summary

Beauty sales expected to increase 11%-13% in the second quarter, driven by a double-digit increase in the U.S., direct-seller reports during Sanford Bernstein Strategic Decisions conference June 3. U.S. sales in Q2 are projected to be up 3%, led by beauty and representative growth, Avon adds. Earnings in the second quarter will increase mid-single digits over year-ago period, firm states. Separately, Avon announced June 4 it has hired talent marketing firm Creative Artists Agency to develop brand-building opportunities in entertainment industry to promote new teen cosmetics initiative mark., which bows in August (1"The Rose Sheet" March 31, 2003, p. 3)...

You may also be interested in...



Avon Aiming For $100 Mil. Mark With Teen Initiative In U.S. In 2004

Avon expects its new mark. teen-targeted cosmetics business to generate U.S. sales of $100 mil. in 2004, the brand's first full year of operation, the direct-seller predicted during a meeting with investors March 28

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.

Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector

With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel